Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
This article was originally published in Drug Channels.
While the U.S. has been frustratingly slow to embrace biosimilars, the next few years are poised to see a veritable boom in…
This article was originally published in PharmExec.
Over the past decade, the life sciences industry has undergone transformative change that has disrupted everything from early drug discovery to post-launch treatment…
While payers’ formulary decisions can make or break a drug’s success, manufacturers within oncology face an additional obstacle to gaining market access: clinical pathways, or guidelines that determine which treatments…
John Griggs co-authored this article with Dinesh Kabaleeswaran. This article was originally published on Drug Channels.
Large healthcare conglomerates, or integrated delivery networks (IDNs), have long been fixtures in the…
People often ask me how MMIT fits into the healthcare ecosystem. MMIT’s mission is to smooth and simplify access to therapies, affecting every part of the continuum from the pharmaceutical…
